MRES: M2Bio Food and Beverage Refocuses Strategy: Expanding Beyond CBD to Reach Global Consumers
M2Bio Food and Beverage, a division of The Institute of Biomedical Research Corp. (OTC PINK:MRES), has announced a strategic shift away from CBD-infused food products. The company cites complex scientific and regulatory challenges associated with CBD as the primary reasons for this decision. Instead, M2Bio will focus on expanding its core offerings, particularly the Liviana® product line, known for premium, organic ingredients.
This pivot is expected to streamline operations and open up broader distribution opportunities, especially in international markets where CBD restrictions have been a barrier. While discontinuing CBD in food products, the company will continue exploring CBD's potential in topical applications for pets with skin conditions. This strategic move aims to enhance value for customers, partners, and shareholders by focusing on areas where M2Bio can more reliably control and optimize health benefits.
M2Bio Food and Beverage, una divisione di The Institute of Biomedical Research Corp. (OTC PINK:MRES), ha annunciato un cambiamento strategico allontanandosi dai prodotti alimentari infusi con CBD. L'azienda cita complesse sfide scientifiche e normative associate al CBD come le ragioni principali di questa decisione. Invece, M2Bio si concentrerà sull'espansione della sua offerta principale, in particolare la linea di prodotti Liviana®, conosciuta per ingredienti premium e biologici.
Questo cambiamento dovrebbe snellire le operazioni e aprire opportunità di distribuzione più ampie, specialmente nei mercati internazionali dove le restrizioni sul CBD sono state un ostacolo. Pur interrompendo l'uso del CBD nei prodotti alimentari, l'azienda continuerà a esplorare il potenziale del CBD per applicazioni topiche per animali domestici con problemi cutanei. Questa mossa strategica punta a migliorare il valore per clienti, partner e azionisti, concentrandosi su aree dove M2Bio può controllare e ottimizzare in modo più affidabile i benefici per la salute.
M2Bio Food and Beverage, una división de The Institute of Biomedical Research Corp. (OTC PINK:MRES), ha anunciado un cambio estratégico alejándose de los productos alimenticios infusionados con CBD. La empresa cita complejas dificultades científicas y regulatorias asociadas con el CBD como las razones principales de esta decisión. En su lugar, M2Bio se centrará en expandir su oferta principal, particularmente la línea de productos Liviana®, conocida por sus ingredientes premium y orgánicos.
Se espera que este cambio optimice las operaciones y abra oportunidades de distribución más amplias, especialmente en mercados internacionales donde las restricciones sobre el CBD han sido una barrera. Aunque se interrumpirá el uso de CBD en productos alimenticios, la empresa seguirá explorando el potencial del CBD en aplicaciones tópicas para mascotas con afecciones cutáneas. Este movimiento estratégico tiene como objetivo mejorar el valor para clientes, socios y accionistas al centrarse en áreas donde M2Bio puede controlar y optimizar más confiablemente los beneficios para la salud.
M2Bio Food and Beverage는 The Institute of Biomedical Research Corp. (OTC PINK:MRES)의 한 부서로서, CBD를 함유한 식품 제품에서 벗어나기로 하는 전략적 전환을 발표했습니다. 회사는 CBD와 관련된 복잡한 과학적 및 규제 문제를 이 결정의 주된 이유로 언급했습니다. 대신, M2Bio는 프리미엄 유기농 재료로 유명한 Liviana® 제품 라인의 확대에 집중할 것입니다.
이번 방향 전환은 운영을 간소화하고 더 폭넓은 유통 기회를 열 것으로 기대되며, 특히 CBD의 제한이 장벽이었던 국제 시장에서 그럴 것입니다. 식품 제품에서 CBD를 중단하더라도 회사는 피부 질환이 있는 반려동물을 위한 국소 적용의 가능성을 계속 탐색할 것입니다. 이 전략적 움직임은 M2Bio가 건강 이점을 보다 신뢰하게 통제하고 최적화할 수 있는 분야에 집중함으로써 고객, 파트너 및 주주를 위한 가치를 향상시키는 것을 목표로 합니다.
M2Bio Food and Beverage, une division de The Institute of Biomedical Research Corp. (OTC PINK:MRES), a annoncé un changement stratégique en s'éloignant des produits alimentaires infusés au CBD. L'entreprise cite les défis scientifiques et réglementaires complexes associés au CBD comme principales raisons de cette décision. Au lieu de cela, M2Bio se concentrera sur l'expansion de ses offres principales, en particulier la gamme de produits Liviana®, connue pour ses ingrédients biologiques haut de gamme.
Ce pivot devrait rationaliser les opérations et ouvrir des opportunités de distribution plus larges, en particulier sur les marchés internationaux où les restrictions sur le CBD étaient un obstacle. Tout en interrompant l'utilisation du CBD dans les produits alimentaires, l'entreprise continuera d'explorer le potentiel du CBD dans les applications topiques pour les animaux de compagnie souffrant de problèmes cutanés. Ce mouvement stratégique vise à améliorer la valeur pour les clients, partenaires et actionnaires en se concentrant sur des domaines où M2Bio peut contrôler et optimiser plus efficacement les bénéfices pour la santé.
M2Bio Food and Beverage, eine Abteilung von The Institute of Biomedical Research Corp. (OTC PINK:MRES), hat einen strategischen Wechsel angekündigt, weg von CBD-infundierten Lebensmitteln. Das Unternehmen nennt komplexe wissenschaftliche und regulatorische Herausforderungen im Zusammenhang mit CBD als die Hauptgründe für diese Entscheidung. Stattdessen wird sich M2Bio darauf konzentrieren, sein Kerngeschäft auszubauen, insbesondere die Produktlinie Liviana®, die für ihre hochwertigen, biologischen Inhaltsstoffe bekannt ist.
Diese Wendung soll die Abläufe straffen und breitere Vertriebsmöglichkeiten eröffnen, insbesondere in internationalen Märkten, wo CBD-Beschränkungen ein Hindernis dargestellt haben. Während CBD in Lebensmitteln eingestellt wird, wird das Unternehmen weiterhin das Potenzial von CBD in topischen Anwendungen für Haustiere mit Hauterkrankungen erkunden. Dieser strategische Schritt zielt darauf ab, den Wert für Kunden, Partner und Aktionäre zu erhöhen, indem er sich auf Bereiche konzentriert, in denen M2Bio Gesundheitvorteile zuverlässiger kontrollieren und optimieren kann.
- Strategic shift to focus on core food and beverage offerings, potentially improving operational efficiency
- Expansion of Liviana® product line, featuring premium organic ingredients
- Anticipated broader distribution opportunities, especially in international markets
- Continued exploration of CBD in topical applications for pets, targeting a specific market niche
- Potential for increased shareholder value through streamlined operations and expanded market reach
- Discontinuation of CBD-infused food product line, potentially resulting in lost revenue from this segment
- Possible sunk costs associated with previous CBD product development and marketing efforts
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 22, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), a pioneering nutraceutical biotechnology company that delves into the innovative realm of plant-based medicines, healthy food products, and sustainable packaging solutions, is pleased to announce the following updates with its M2Bio Food and Beverage division:
M2Bio Food and Beverage, known for its premium, healthy, and sustainably sourced products, is taking a significant step forward by announcing a strategic shift in its product lineup. After several successful years of exploring CBD-infused food products, the company has decided to discontinue this line and refocus efforts on expanding its core offerings.
This decision is rooted in the complex scientific and regulatory landscape surrounding CBD. While CBD has shown promise in various health applications, particularly in its anti-inflammatory and neuroprotective effects, the challenges associated with its use in food products have proven to be substantial. Research indicates that the bioavailability of CBD when ingested in food can vary widely, leading to inconsistent dosing and efficacy. Furthermore, the ongoing global debate and regulatory uncertainty over the classification of CBD as a food ingredient have added complexity to its marketability.
"We've always been committed to innovation, and our foray into the CBD space was driven by a desire to explore its potential benefits in food products," says M2Bio Food and Beverage CEO Michael Sachar. "However, it's just as important to recognize when the scientific, regulatory, and logistical challenges outweigh the benefits. By pivoting away from CBD in our food products, we can streamline our operations and focus on what we do best-delivering high-quality, sustainably sourced foods that our customers trust and love."
This strategic pivot is a response to the challenges encountered and an opportunity to enhance the company's offerings further. The Liviana® product line, known for its premium, organic ingredients, is poised to benefit from this refocus. Without the complications associated with CBD, M2Bio Food and Beverage anticipates broader distribution opportunities, particularly in international markets where CBD restrictions have previously posed significant barriers.
While the company is stepping back from CBD in food, its commitment to research and development in the health and wellness sector remains steadfast. M2Bio Food and Beverage will continue to explore the therapeutic potential of CBD in topical applications, particularly for pets suffering from skin conditions. Early studies suggest that CBD's anti-inflammatory properties could relieve pets with dermatitis, a common and often chronic condition.
Jeff Robinson, CEO of M2Bio Sciences, commented on the scientific considerations driving this decision: "The bioavailability and pharmacokinetics of CBD when incorporated into food products present significant challenges. Our research indicates that achieving consistent therapeutic outcomes through ingestion is complex due to variability in absorption and metabolism. By redirecting our focus away from CBD-infused foods, we are positioning ourselves to advance in areas where we can more reliably control and optimize the health benefits of our products. This shift also opens up the entire global market to us, free from the regulatory constraints and distribution barriers that CBD imposed, allowing us to bring our products to consumers worldwide with greater ease and efficiency."
As M2Bio Food and Beverage embarks on this new chapter, the company is very optimistic about the future. This strategic decision will unlock new growth opportunities, allowing the company to deliver greater value to its customers, partners, and shareholders.
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp., trading as M2Bio Sciences, is a bioceutical company focused on alternative plant-based therapies and mental health therapeutic research. M2Bio's mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.
M2Bio conducts research at the M2Bio Discovery Centre for AI-Driven Phytomedicine Research at the University of Pretoria in South Africa. The research aims to provide scientific validation for the Company's expanding product range, including innovative plant-based medicines.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES." Publicly traded Company (OTC Pink:MRES)
Contact:
Jeff Robinson, CEO
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Forward-Looking Statement:
This release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief, or current expectations of Real American Capital Corp., its directors, or its officers concerning, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy.
Jeff Robinson
M2Bio Sciences Food and Beverage (Pty) Ltd
72 333 2148
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
TikTok
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Contact Information
Jeff Robinson
Chairman and CEO: M2Bio Sciences
jeff@m2bio.co
+27723332148
Related Images
|
SOURCE: M2Bio Sciences
View the original press release on accesswire.com
FAQ
Why is M2Bio Food and Beverage discontinuing its CBD-infused food products?
What will M2Bio Food and Beverage focus on after discontinuing CBD products?
Will M2Bio Sciences (MRES) continue any CBD-related research?
How might this strategic shift impact M2Bio Sciences' (MRES) market reach?
